BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/26/2025 10:27:29 AM | Browse: 73 | Download: 256
 |
Received |
|
2025-06-13 08:40 |
|
Peer-Review Started |
|
2025-06-13 08:41 |
|
First Decision by Editorial Office Director |
|
2025-07-14 07:06 |
|
Return for Revision |
|
2025-07-14 07:06 |
|
Revised |
|
2025-07-24 23:57 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-07 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-07 11:05 |
|
Articles in Press |
|
2025-11-07 11:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-18 02:14 |
|
Publish the Manuscript Online |
|
2025-12-26 10:27 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Basic Study |
| Article Title |
Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-ɑ pathway to modulate hepatic ischemia reperfusion-induced injury
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mina Thabet Kelleni, Walaa Yehia Abdelzaher, Marly Adly, Mina Ezzat Attya, Michael A Fawzy and Mohamed Abdellah Ibrahim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mina Thabet Kelleni, Assistant Professor, MD, PhD, Department of Medical Pharmacology, College of Medicine, Minia University, Main Road Shalaby Land, Minia 61519, Egypt. mina.kelleni@mu.edu.eg |
| Key Words |
Hepatic ischemia reperfusion injury; Aprepitant; Sirtuin 1; Nuclear factor erythroid-2-related factor 2; Tumor necrosis factor alpha |
| Core Tip |
This study demonstrates that aprepitant, a neurokinin-1 receptor antagonist, exerts hepatoprotective effects in a rat model of hepatic ischemia reperfusion by modulating the sirtuin 1/nuclear factor erythroid-2-related factor 2/tumor necrosis factor alpha signaling pathway. Aprepitant significantly reduced hepatic enzyme elevation, oxidative stress parameters, inflammatory cytokines, and apoptosis markers, while enhancing the pluripotent capacity of sirtuin 1/nuclear factor erythroid-2-related factor 2 expression, highlighting its potential as a therapeutic agent to mitigate HIR-induced liver injury during major liver surgeries, as well as highlighting the significant therapeutic pharmacological potential while targeting this pathway by other current and future drugs. |
| Publish Date |
2025-12-26 10:27 |
| Citation |
Kelleni MT, Abdelzaher WY, Adly M, Attya ME, Fawzy MA, Ibrahim MA. Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-ɑ pathway to modulate hepatic ischemia reperfusion-induced injury. World J Hepatol 2025; 17(12): 110733 |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i12/110733.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i12.110733 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
